FDA Approves Tool for Blood Cancer Detection

ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.
 
BY SILAS INMAN @silasinman
PUBLISHED: JUNE 30, 2017
ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, acute leukemia, non-Hodgkin lymphoma, multiple myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). This is the first approval the agency received for immunophenotyping on a flow cytometer.

The approval was based on the effectiveness of the screening panel compared with alternative methods for the detection of leukemias and lymphomas in 279 samples at four independent clinical sites. Overall, findings from the ClearLLab reagents aligned with standard methods in 93.4 percent of the samples. Additionally, the diagnostic correctly detected cancer in 84.2 percent of samples.

“This represents a major step forward for the hematology-oncology community,” Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, said in a statement. “Laboratories and healthcare professionals now have access to an FDA-validated test that provides consistent results to aid in the diagnoses of these serious cancers.”

The reagents can be used on peripheral whole blood, bone marrow, and lymph node specimens. Each of the ClearLLab reagents (T1, T2, B1, B2, M) is specific to CD45, which is expressed on a variety of leukocyte populations. This marker is used as a gating agent for the tests, to correlate results. CD45 is expressed on hematopoietic cells but not differentiated nonhematopoietic tissue.

In addition to CD45, the tests provide qualitative results for several other factors associated with hematologic malignancies. The T1 reagents illuminate CD2, CD56, CD7, and CD5. T2 is specific to CD8, CD4 and CD3. The B1 test detects Kappa, Lambda, CD19 and CD5 while B2 is specific to CD20, CD10, CD19 and CD38. The M test detects CD7, CD13, CD34 and CD33.

The antigens illuminated by the T1 and T2 reagents are found on a T and natural killer (NK) cell populations. These reagents can be used along with clinical parameters for the detection of T-cell lymphoblastic leukemia/lymphoma. The B1 and B2 reagents, which detect a variety of B cell specific antigens, have shown promise at uncovering B-cell lymphoblastic leukemia/lymphoma. These B cell surface antigens, along with Kappa and Lambda, typically express starting with CD19 followed by CD20. The M reagent is geared primarily toward myeloid cells, and can effectively be used to uncover acute myeloid leukemia.

Across the study that was instrumental in the approval, the multicolor reagents passed all equivalency tests compared with single color conjugate reagents. The mean difference between the multi- and single-color tests ranged from -1.1 to 0.6. The precision varied for each positive antigen detected.

In the T1/T2 groups, the lowest coefficients of variation (CV) for repeatability were seen for CD2+ and CD3+ cells (0.76 percent and 0.79 percent, respectively). The CV was 3.32 percent for CD56+ cells and 1.22 percent and 1.89 percent for both CD3+/CD4+ and CD3+/CD8+ cells, respectively.

The CV rates were slightly higher in the B1 and B2 groups. For CD19+ the B1 reagents had a CV of 2.63 percent and for the B2 reagents the CV was 2.58 percent. The CV for CD20 was 2.92 percent. For the combination of CD19+ and Kappa+, the CV was 2.78 percent and for CD19+ and Lambda+, the CV was 3.71 percent. For the M reagents, all CV rates were low for CD7+, CD13+, and CD33+ (range, 0.40 percent to 0.95 percent). For the CD34+ antigens, the CV rate was 6.65 percent.
 
 

Talk about this article with other patients, caregivers, and advocates in the Myelodysplastic syndrome CURE discussion group.
x-button
 
CURE wants to hear from you! We are inviting you to Share Your Story with the readers of CURE. Submit your personal experience with cancer by visiting Share Your Story
 
Not yet receiving CURE in your mailbox? Sign up to receive CURE Magazine by visiting GetCureNow.com
x